HEL 92.1.7 Cells
| Unit |
5 x 10^6 cells/ml |
|---|---|
| Cell Type |
Tumor Cells |
| Tissue Type |
Leukemia cell lines |
| Organism |
Human |
| Donor History |
Erythroleukemia |
| Growth Properties |
Suspension |
| Growth Conditions |
Culture medium: RPMI 1640 ,w: 2.0 mM stable Glutamine ,w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% heat-inactivated FBS. Dissociation reagent: Accutase. Freeze medium: As a cryopreservation medium ,we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability ,or CM-1 (Cytion catalog number 800100) ,which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C ,5% CO2 ,humidified atmosphere. |
| Immortalization Method | |
| Full Information |
The HEL 92.1.7 cell line exhibits the capacity for spontaneous differentiation into erythroblast-like cells, mimicking some aspects of erythroid maturation in vitro. This characteristic makes them particularly useful for studying the erythroid differentiation process and the regulation of gene expression related to erythropoiesis. Their ability to spontaneously differentiate offers a unique advantage for studying the intrinsic pathways and mechanisms that drive erythroid precursor maturation without the addition of external differentiation-inducing agents.
Moreover, the differentiation of HEL 92.1.7 cells can be further manipulated through the addition of phorbol esters such as TPA (12-O-tetradecanoyl-phorbol-13-acetate) and PMA (phorbol myristic acid), which are known to induce macrophage-like differentiation. This induced differentiation into macrophage-like cells expands the utility of the HEL 92.1.7 cell line beyond erythroid studies, allowing researchers to explore and understand the plasticity of hematopoietic cells and the conditions under which lineage commitment and cellular identity can be redirected. Such studies are crucial for developing therapeutic strategies aimed at manipulating cell fate for regenerative medicine and cancer treatment.
Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.
Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.
Mikrobiologické aplikace
NGS
Rapid testy
PCR plasty
Třepačky
Suché lázně
Fluorometry
Buněčné kultury
PCR, qPCR, RT
Detekce Mycoplasmat
Reverzní transkripce
Alergie
Intolerance
Elisa
Imunologické analyzátory
Veterinární imunologie
Alergie u zvířat
Intolerance u zvířat
Čtečky identifikačních čipů
Termočipy
Biochemie
Imunoanalýza

